EUVIMEDEUVIMED entdecken
Open Access

Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer

Nathan Poterszman, Cécile Hammer-Lefevre, Clémence Porot, Julien Salvadori, Philippe Barthélémy, François Somme

Theranostics · 2025

DOI: 10.7150/thno.109860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Nathan Poterszman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, Strasbourg, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Prostate-Specific Antigen, Dipeptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingProstate-Specific AntigenDipeptidesBlood PlateletsHumansMaleAgedRetrospective StudiesLutetiumMiddle AgedAged, 80 and overTreatment OutcomePlatelet CountBiomarkers, TumorNeoplasm MetastasisPrognosisRadiopharmaceuticalsRadioisotopes

Stichwörter der Autor:innen

[177Lu]Lu-PSMA-617metastatic castration-resistant prostate cancer (mCRPC)personalized oncologypredictive factorsradioligand therapy

Substanzen

Heterocyclic Compounds, 1-RingProstate-Specific AntigenDipeptidesLutetiumPluvictoBiomarkers, TumorLutetium-177RadiopharmaceuticalsRadioisotopes

Autor:innen und Institutionen

  • Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Radiopharmacy, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Radiophysics, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.

Zitieren

APA

Poterszman, N., Hammer-Lefevre, C., Porot, C., Salvadori, J., Barthélémy, P., & Somme, F. (2025). Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer. Theranostics. https://doi.org/10.7150/thno.109860

Vancouver

Poterszman N, Hammer-Lefevre C, Porot C, Salvadori J, Barthélémy P, Somme F. Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer. Theranostics. 2025. doi:10.7150/thno.109860

BibTeX
@article{Poterszman2025,
  author = {Poterszman, Nathan and Hammer-Lefevre, Cécile and Porot, Clémence and Salvadori, Julien and Barthélémy, Philippe and Somme, François},
  title = {Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [ 177 Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer},
  journal = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.109860}
}
Kostenlos starten →